跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

安全信息

EHU013781

Sigma-Aldrich

MISSION® esiRNA

targeting human VEGFC

登录查看公司和协议定价
所有图片(1)

About This Item

UNSPSC代码:
41105324
NACRES:
NA.51

描述

Powered by Eupheria Biotech

质量水平

100

产品线

MISSION®

表单

lyophilized powder

esiRNA cDNA靶序列

AGCAAAGATCTGGAGGAGCAGTTACGGTCTGTGTCCAGTGTAGATGAACTCATGACTGTACTCTACCCAGAATATTGGAAAATGTACAAGTGTCAGCTAAGGAAAGGAGGCTGGCAACATAACAGAGAACAGGCCAACCTCAACTCAAGGACAGAAGAGACTATAAAATTTGCTGCAGCACATTATAATACAGAGATCTTGAAAAGTATTGATAATGAGTGGAGAAAGACTCAATGCATGCCACGGGAGGTGTGTATAGATGTGGGGAAGGAGTTTGGAGTCGCGACAAACACCTTCTTTAAACCTCCATGTGTGTCCGTCTACAGATGTGGGGGTTGCTGCAATAGTGAGGGGCTGCAGTGCATGAACACCAGCACGAGCTACCTCAGCAAGACGTTATTTGAAATTACAGTGCCTCTCTCTCAAGGC

基因组数据库 |人类登记号

ENSG00000150630

NCBI登记号

NM_005429

运输

ambient

储存温度

−20°C

基因信息

human ... VEGFC(7424) , VEGFC(7424)

一般描述

MISSION® shRNA是核糖核酸内切酶制备的siRNA。它们是靶向相同mRNA序列的siRNA异质混合物。这些多重沉默触发（multiple silencing trigger）导致高度特异性的、有效的基因沉默。

如需其他详细信息并查看所有可用的esiRNA选项，请访问SigmaAldrich.com/esiRNA。

法律信息

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

储存分类代码

12 - Non Combustible Liquids

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
SUU
IUU
ISU
PNU
QCS

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Signe R Michaelsen et al.
Neuro-oncology, 20(11), 1462-1474 (2018-06-26)
Glioblastoma ranks among the most lethal cancers, with current therapies offering only palliation. Paracrine vascular endothelial growth factor (VEGF) signaling has been targeted using anti-angiogenic agents, whereas autocrine VEGF/VEGF receptor 2 (VEGFR2) signaling is poorly understood. Bevacizumab resistance of VEGFR2-expressing
Bo Sun et al.
International journal of cancer, 145(6), 1648-1659 (2019-02-09)
The lymphatic network remodeling may guide tumor metastasis in a sentinel lymph node (SLN). Although tumor-derived exosomes have been demonstrated to modify the microenvironment in adjacent organs and initiate a premetastatic niche, their influence on the lymphatic network in SLNs
Erin Regan et al.
PloS one, 11(3), e0150963-e0150963 (2016-03-08)
It is well established that lung tumors induce the formation of lymphatic vessels. However, the molecular mechanisms controlling tumor lymphangiogenesis in lung cancer have not been fully delineated. In the present study, we identify a panel of non-small cell lung

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门